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Abstract The selective BRAF inhibitors vemurafenib and
dabrafenib yield high response rates and improved overall sur-
vival in patients with BRAF V600E-mutant metastatic melano-
ma. Treatment traditionally continues until disease progression
or the development of unacceptable toxicity. Acquired drug re-
sistance and toxicity are key challenges with the use of these
drugs. Resistance to vemurafenib usually develops within 6–
8 months. Management of drug toxicity typically involves stop-
ping vemurafenib until resolution, before restarting at a lower
dose, or permanently ceasing vemurafenib therapy. We have
recently considered whether intermittent dosing could be used
as an alternative to dose reduction/termination in the manage-
ment of vemurafenib toxicity. One patient treated with intermit-
tent vemurafenib was an 89-year-old woman with metastatic
melanoma, who initially showed a good response to continuous
dosing. Recurrent toxicity meant that the continuous
vemurafenib dosage was repeatedly ceased before restarting at
a lower dose. Ten months after vemurafenib was first begun, an
intermittent dosing regimen was introduced in an attempt to
control toxicity. This continued for 2 months, before cessation
due to continued unacceptable toxicity. A further 24 months
later, the patient remains fit and well in complete clinical remis-
sion, with no recurrence of her previous melanoma and no new
primary malignancies. To the best of our knowledge, a contin-
ued response after the cessation of selective BRAF inhibitors has
never before been described in melanoma. Induction of an im-
mune response and/or epigenetic changes could explain contin-
ued disease response after cessation of vemurafenib therapy.
Care should be taken when extrapolating the findings from the
continued response after vemurafenib cessation to other tumour
types. We recommend the collection and analysis of data to
investigate the clinical responses seen after cessation of
vemurafenib due to intolerable toxicities, which could help fur-
ther explain vemurafenib’s mechanism of action.
1 Background
The v-raf murine sarcoma viral oncogene homolog B1
(BRAF) gene is mutated in 40–60 % of melanomas, the most
common being the V600E mutation, which leads to over-
activation of the mitogen-activated protein kinase (MAPK)
pathway [1, 2]. The selective BRAF inhibitors vemurafenib
and dabrafenib yield high response rates and improved overall
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Key Points
We have previously described the use of intermittent 
vemurafenib as an alternative to dose reduction/termination 
in the management of vemurafenib toxicity.
The selective BRAF inhibitors, vemurafenib and dabrafenib,
yield high response rates and improved overall survival in 
patients with BRAF V600E-mutant metastatic melanoma.
One patient previously described has shown a continued 
response after ceasing intermittent vemurafenib. A continued 
response after the cessation of selective BRAF inhibitors has
never been previously described in melanoma.
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survival in patients with BRAF V600E-mutant metastatic
melanoma [3, 4]. However, acquired drug resistance and drug
toxicity are key challenges with the use of these drugs. Resis-
tance to vemurafenib usually develops within 6–8 months [5].
In the BRAF Inhibitor inMelanoma-3 (BRIM-3) trial, a phase
3 randomised open-label study comparing vemurafenib with
dacarbazine in BRAF V600E- and BRAF V600K-mutant
melanoma, 38 % of patients receiving vemurafenib required
dose modifications because of toxicity [3]. Management of
toxicity typically involves stopping vemurafenib until resolu-
tion, before restarting at a lower dose, or permanently ceasing
vemurafenib therapy. In an extended follow-up of BRIM-3,
treatment was discontinued because of adverse events in 24
patients receiving vemurafenib and six patients receiving
dacarbazine. No data were presented on the outcome of these
patients after cessation of therapy due to unacceptable toxic-
ities [6]. Although disease progression has traditionally been
seen as the point at which vemurafenib therapy should cease,
recent research has suggested that treatment beyond progres-
sion might be beneficial [7]. Acquired resistance to targeted
therapies is also a challenge in the treatment of non-small cell
lung cancer (NSCLC). Epidermal growth factor receptor
(EGFR) inhibitors such as gefitinib, erlotinib and axitinib are
standard first-line treatments for patients with NSCLC with
activating EGFR mutations [8]. Unfortunately, most patients
eventually acquire resistance, and management options after
progression on EGFRTKIs have yet to be defined [9, 10]. The
recent IMPRESS trial investigated whether targeted therapies
should be continued after progression. The study concluded
that continuation of gefitinib after radiological disease pro-
gression on first-line gefitinib did not prolong progression-
free survival in patients who received platinum-based doublet
chemotherapy as a subsequent line of treatment [8].
We recently presented a case series in which patients
with intolerable toxicities on a continuous dosing regi-
men of vemurafenib were treated instead with an inter-
mittent regimen. Our experience showed that intermit-
tent dosing could successfully manage vemurafenib tox-
icities where continuous dosing at a reduced dose did
not, while maintaining or achieving melanoma shrink-
age. We therefore recommended that intermittent dosing
should be considered as an alternative to dose reduction/
termination in the management of vemurafenib toxicity
[11]. While we could present no evidence that intermit-
tent therapy is more effective than continuous therapy,
or that it can prevent the appearance of drug-resistant
disease, this is due to be investigated in clinical trials
currently in set-up. In animal models, however, there is
evidence which suggests that intermittent dosing of
vemurafenib can forestall the emergence of resistance
[12]. This study of an animal model of melanoma did
not investigate whether intermittent dosing continued to
exert an effect after cessation.
2 The Case
We previously reported the case of an 88-year-old woman
diagnosed with metastatic melanoma who showed a good
response to vemurafenib despite several dose reductions due
to toxicity [11].
She originally had a superficial spreading melanoma re-
moved from her left leg in 2006 when she was 80 years old.
The primary melanoma had a Breslow thickness of 1.5 mm and
was non-ulcerated, with a mitotic index of 0.1–0.5 per mm2. No
adjuvant therapy was given afterwards. A further melanoma
was excised from the left leg in 2007 (again a superficial spread-
ing melanoma, non-ulcerated, Breslow thickness 2.5 mm, mi-
totic count 3 per mm2). The patient continued on surveillance
follow-up. She remained well until 2011, when she developed
multiple rapidly growing and painful subcutaneous lesions
along her left leg, confirmed as melanoma on biopsy. A CTscan
in November 2011 showed two 11-mm nodules in the right
lung, suggesting small-volume metastatic disease. Her melano-
ma was confirmed as containing the BRAF V600E mutation,
and shewas commenced on vemurafenib at the standard starting
dose of 960 mg twice daily (BD) in January 2012, as part of an
expanded access programme. A further CT scan just before
starting treatment showed disease progression, with multiple
small-volume pulmonary nodules and multiple enlarged left in-
guinal lymph nodes. Clinically, the disease in her left leg had
also worsened. Pre-treatment LDH was elevated at 262 IU/L
(normal range: 110–255).
The patient showed a rapid clinical response to therapy,
with a reduction in the leg lesions within 4 weeks of starting
treatment. However, she also experienced various toxicities,
particularly joint pain and nausea. After 8 weeks of therapy, a
CT scan showed the majority of pulmonary nodules and in-
guinal lymph nodes had either significantly shrunk or
completely resolved. One nodule in the left lower lobe, how-
ever, had enlarged. A further CT scan after 16 weeks of ther-
apy showed the left lower lobe pulmonary nodule remained
unaltered with no newmetastases. Clinically, the lesions in her
left leg continued to shrink. However, by week 24 of therapy,
she had lost 14 kg and developed grade 2 nausea and diar-
rhoea. Vemurafenib was ceased at this point. These toxicities
quickly resolved, so therapy was restarted a week later at a
lower dose of 720 mg BD. However, the patient again devel-
oped toxicity within less than 2 weeks. Treatment was again
ceased for 1 week, before restarting at 480 mg BD. Treatment
continued at this lower dose for 8 weeks, before a further 1-
week cessation due to toxicities. This pattern continued, with
toxicity settling whilst off treatment but quickly re-emerging
on restarting therapy. So, in November 2012, 10 months after
initially starting vemurafenib, with CT and clinical evidence
of ongoing response, a decision was made to recommence
vemurafenib on an intermittent regimen of 480 mg BD, 1
week on, 1 week off. As this could not be done within the
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expanded access programme, we applied for and received ap-
proval for this to be funded through the Cancer Drugs Fund. The
lesions on the left leg continued to shrink on intermittent dosing,
and 1 month later the leg was clear of all visible deposits. How-
ever, intermittent dosing was ceased in January 2013 because of
grade 2 arthralgia in the patient’s hands. A CTscan performed 4
weeks after cessation of vemurafenib showed an ongoing
response, with no evidence of any metastatic disease. The
marker left inguinal lymph node remained unchanged in size.
We planned to restart vemurafenib as and when the leg lesions
recurred, but so far this has not occurred. As of February 2015,
the patient is alive and clinically free of disease. She has not
needed any other treatment for her metastatic melanoma. A
summary of her clinical history is presented in Table 1.
3 Discussion
To the best of our knowledge, a continued response after ceas-
ing vemurafenib has not been previously described in metasta-
tic melanoma. The melanoma showed a rapid response soon
after starting vemurafenib on a continuous dosing regimen.
This response continued on intermittent dosing, with the leg
lesions continuing to shrink until they completely disappeared.
We feared the disease would recur soon after vemurafenib was
ceased. However, the complete response has continued for over
2 years after cessation of therapy. It is difficult to understand
what role, if any, intermittent therapy played in this continued
response, especially since such a rapid, although not universal,
response to continuous dosing was seen. Although the patient is
in complete clinical remission, this does not mean the melano-
ma has been completely eliminated. It is possible there are small
areas of residual disease left in this patient, and recurrence could
yet occurmany years later. Since late recurrence ofmelanoma is
not uncommon, no melanoma patient, including the one de-
tailed in this report, can ever be considered cured [13].
3.1 Continued Response in Non-Melanoma BRAF
Mutated Cancer
A continued response after ceasing vemurafenib therapy has
been described in a patient with BRAF V600E-mutant hairy
cell leukaemia (HCL) [14]. Briefly, this patient was treated
with multiple lines of conventional therapy, but none proved
effective. The presence of a V600E mutation was demonstrat-
ed, and so the patient was started on vemurafenib. The patient
showed a rapid response to treatment within days, with a re-
duction in splenomegaly and rise in platelet, haemoglobin,
and leukocyte counts. By day 35, flow cytometry showed no
evidence of HCL cells in peripheral blood. The patient was
treated with vemurafenib for a total of 56 days; the decision to
cease therapy was made at this point because of the excellent
response to treatment and to avoid cutaneous toxicities.
Despite discontinuation of vemurafenib, the patient remained
in remission, with no evidence of minimal residual disease
6months after stopping treatment. Analysis of trephine biopsies
obtained before and during treatment demonstrated abolition of
ERK phosphorylation in HCL cells within 6 days of starting
vemurafenib, resulting in apoptosis of the leukemic cells [14].
These findings support the conclusions drawn by in vitro work
performed by Tiacci et al., in which BRAF-mutated HCL cells
were shown to be highly sensitive to BRAF inhibition [15].
In the BRAF-mutant HCL patient who showed a continued
response after ceasing vemurafenib, the drug appeared to me-
diate its effect by inhibiting the MAPK pathway. This is the
same pathway targeted by vemurafenib in BRAF-mutant mel-
anoma [16]. However, the continued clinical responses seen in
these two cases are not necessarily the same phenomena. In
the HCL case, the rapid elimination of all detectable HCL cells
suggests that vemurafenib is acting on a homogenous clonal
population of BRAF-mutant HCL cells. In our patient with
melanoma, the response in most lesions, but the increase and
subsequent stabilisation in one pulmonary lesion, suggests
activity against a more heterogenous tumour population.
Although it is likely that MAPK pathway inhibition is nec-
essary for clinical effectiveness of vemurafenib in both mela-
noma and HCL, different biochemical pathways may be in-
volved. The genetic basis of HCL is not fully understood, but
pathways involving FLT3L and IL3 appear to play an important
role in protecting HCL cells from apoptosis [17]. In melanoma,
different pathways are involved, such as the CDKN2A/CDK4
system and pathways involving the extracellular matrix not
found in HCL [18, 19]. In the HCL case described above, it
appears that BRAF inhibition interrupted signalling through
MEK and ERK, which led to apoptosis in all of the clonal
HCL cells, resulting (in this one case) in the effective elimina-
tion of the entire tumour population [14]. This suggests that all
the BRAF-mutant HCL cells were dependent on aberrant
BRAF signalling for survival. In BRAF-mutant melanoma,
targeting the MAPK pathway alone is not sufficient to induce
apoptosis in the entire tumour population. Much work on resis-
tance to BRAF inhibition in melanoma has been done, and
activation of the parallel PI3k/AKT pathway appears to play
an important role [5, 20]. Although current understanding of
HCL genetics is incomplete, the BRAF V600E mutation is
found in the vast majority of HCL cases, compared with the
40–60 % of melanomas that contain a range of BRAF muta-
tions [1, 21, 22]. Melanoma is the most mutated tumour in
oncology, suggesting the presence of numerous alternate path-
ways that could play a role in resistance development [23].
There is now good evidence that melanoma metastases
can be genetically heterogeneous, with genetic differences
found both between and within different melanoma metas-
tases in a single patient [24]. It is likely that different me-
tastases will show different characteristics, both in terms of
their natural history and in their response to vemurafenib.
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In this case report, the majority of melanoma metastases
were very sensitive to vemurafenib, suggesting that the
drug acted on these lesions directly through inhibition of
ERK phosphorylation and subsequent apoptosis of cancer
cells, as with the HCL case. However, the fact that one
pulmonary lesion initially grew suggests it had less depen-
dence on the MAPK pathway. The subsequent growth ar-
rest with continued vemurafenib treatment suggests that the
drug eventually worked via a different mechanism (possi-
bly an immune-mediated response).
3.2 Possible Explanations for the Continued Response
There are several possible explanations as to why the disease
did not progress after cessation of treatment in the case of our
patient. Firstly, the natural history of the disease needs to be
understood; it could be that this patient had an indolent form
of melanoma. Our patient is female; there is a much more
favourable long-term survival for women after development
of distant metastases [25]. However, we feel that this is an
unlikely explanation for this patient, given that prior to starting
vemurafenib, the melanoma was growing rapidly, especially
the leg lesions.
Other potential mechanisms by which vemurafenib could
produce a lasting response, even after cessation of treatment,
could include the induction of an immune response and/or
epigenetic mechanisms.
3.3 Epigenetic Modification
It is increasingly understood that epigenetics plays a role
in the pathogenesis of cancer, and several epigenetic
modifiers are in development, where the drug targets
enzymes involved in epigenetic control of gene expres-
sion. These targets include DNA methyltransferases and
acetyltransferases. Epigenetic modifiers such as
azacitidine (a DNA methyltransferase) and vorinostat (a
histone deacetylase) are now approved cancer therapies
[26]. Epigenetic modification of gene expression can re-
sult in the drug continuing to exert its effect long after
its administration has been ceased [27]. It is plausible
that BRAF inhibition could induce epigenetic changes,
leading to long-term effects which last beyond drug
treatment. Given that acquired resistance to BRAF inhib-
itors in melanoma is likely due to upregulation of alter-
native pathways, it is plausible that epigenetic regulation
plays a role in acquired resistance [5]. In our experience,
after stopping continuous dosing of vemurafenib, there is
often rapid progression of disease. Here, the fact that this
patient was treated with intermittent therapy could be an
important factor in the ongoing complete response after
ceasing therapy, since it might have changed the epige-
netic profile of the melanoma in a beneficial way that
could not be achieved with continuous dosing. Work in
animal studies has shown that intermittent therapy can
prevent acquired resistance [12]. Further research inves-
tigating whether response to treatment continues after
ceasing intermittent vemurafenib and how intermittent
treatment affects the epigenetic profile of tumours would
be helpful.
3.4 Immune Induction
It is now clear that the immune system plays an important
role in melanoma. Partial regression of primary cutaneous
melanomas is a common event, though complete regres-
sion is rare [28]. Spontaneous regression of metastatic
melanoma is very rare [29]. There are many potential
mechanisms by which this might occur, but the most like-
ly is the activation of the immune system to produce a
greater than normal response. Many immunomodulating
drugs have now been shown as effective treatments in
melanoma. Interferon-α2 and interleukin 2 are approved
for use in an adjuvant setting in selected cases [30, 31].
Ipilimumab is an anti-CTLA-4 monoclonal antibody
which augments T-cell activation. Ipilimumab was the
first drug to improve overall survival in the metastatic
setting [32]. IMCgp100 is a novel immunotherapy cur-
rently in phase 1 trials [33]. Perhaps most significant
has been the development of PD-1 inhibitors. Nivolumab
and pembrolizumab are both PD-1 inhibitors approved for
the treatment of melanoma in the US and in Europe
[34–36].
Recently, there has been interest in whether inhibiting
the MAPK pathway up-regulates the immune response
against melanoma metastases. If this is the case, it could
provide a possible explanation for the ongoing complete
response after vemurafenib therapy was ceased in our pa-
tient. One study, in which biopsies were taken from pa-
tients before and after starting vemurafenib therapy,
showed that BRAF inhibition was associated with in-
creased melanoma antigen expression, increased CD8+ T-
cell infiltrate and decreased immunosuppressive cytokines
in tumours of patients with metastatic melanoma. When
patients progressed, biopsies were again taken, showing
that melanoma antigen expression and CD8+ T-cell infil-
trate were decreased at the time of progression [37]. These
findings would be consistent with a model where de-
creased immune response allows the tumour to escape im-
mune surveillance and therefore progress. Animal studies
have shown that host immunity can contribute to the anti-
tumour activity of BRAF inhibition, with CCR2 suggested
as an important participant [38]. It would be of interest to
determine whether intermittent vemurafenib is associated
with increased markers of an immune response compared
with continuous vemurafenib. It would also be of interest
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to assess whether concurrent treatment with immunosup-
pressants, such as steroids, affects response to therapy with
vemurafenib. Studies investigating the combination of
BRAF inhibitors and immunotherapy in the treatment of
metastatic melanoma are ongoing [38, 39]. Combined
BRAF and MEK inhibition has now been found to be more
effective that BRAF inhibition alone [40]. The effect of
this combination on the immune system warrants further
investigation.
It is worth noting that in our case, the patient suffered
numerous toxicities which are possibly immune-related, par-
ticularly arthralgia. These continued despite dose reductions,
and for some time after vemurafenib cessation. This may sug-
gest that immune induction played a greater role in this patient
than is typical with vemurafenib. That the response to therapy
was rapid does not necessarily exclude an underlying immune
component. Recent clinical trials combining ipilimumab and
nivolumab in advanced melanoma have shown that over 80%
reduction in target lesion size within 6–12 weeks is not un-
common [41].
4 Summary
In summary, over 24 months after ceasing intermittent
vemurafenib therapy due to unacceptable toxicities, the pa-
tient described in this case remains well, with continued clin-
ical complete response. To the best of our knowledge, a con-
tinued response of metastatic melanoma to vemurafenib after
ceasing treatment has never before been described. Under-
standing how this occurred could provide greater insight into
how vemurafenib exerts its effect in BRAF-mutant metastatic
melanoma. We recommend follow-up of other patients who
have had to cease vemurafenib due to unacceptable toxicities,
in order to see how common the occurrence of continued
response is after cessation of vemurafenib therapy, and wheth-
er the toxicity experienced can provide clues as to other mech-
anisms of action of this drug, beyond simple inhibition of the
MAPK pathway.
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